Texas AG Ken Paxton has sued Johnson & Johnson and Kenvue, alleging they hid Tylenol’s pregnancy risks despite no proven ...
The consumer healthcare company currently trades at about 15x earnings multiple, which represents a 9.41% undervaluation ...
Texas Attorney General Ken Paxton claims the makers of Tylenol failed to warn consumers of the risks. Here's who makes ...
As the consumer health company battles claims from the Trump administration that its painkiller Tylenol is linked to autism, Kenvue will bring on Halvorson as its next marketing chief.
Texas Attorney General Ken Paxton is suing the makers of Tylenol over allegedly deceptively marketing the over-the-counter ...
NRG Therapeutics made three senior appointments in newly created roles: Sarah Almond as VP of translational biology; David Brocklebank as director of clinical operations and Kathryn Oliver as director ...
A potential legal headache for consumer healthcare giant Kenvue (NYSE: KVUE) was causing pain for investors on Thursday. Such ...
Kenvue Inc. (NYSE: KVUE) will announce its third quarter 2025 financial results before the market opens on November 6, 2025.
Kenvue faces declining sales and high debt post-spin-off. Read why a dividend cut may be imminent and why KVUE stock is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results